Anti-amyloid antibody landscape, 2026 mid-year reference
A dated reference snapshot of the anti-amyloid antibody class for Alzheimer's disease as of mid-2026: approved products, withdrawn products, late-stage pipeline, label-defining clinical evidence, and the operational pattern that defines the class.
The anti-amyloid antibody class for Alzheimer's disease, mid-2026: two approved products (lecanemab, donanemab), one withdrawn (aducanumab), and a small pipeline (trontinemab, remternetug). PanaceaIntel covers the dated reference state of the class - approvals, mechanisms, dosing protocols, pivotal-trial signal, and what is most likely to change in the next 6-12 months.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Key sources
- FDA prescribing information for Leqembi (lecanemab-irmb)
- FDA prescribing information for Kisunla (donanemab-azbt)
- CLARITY AD published results - NEJM 2023
- TRAILBLAZER-ALZ 2 published results - JAMA 2023
- Biogen aducanumab withdrawal announcement, January 2024
Related
- SignalGenetically-targeted Parkinson's programs reach pivotal data
- ExplainedWhat is the FDA accelerated approval pathway, and why does it matter for Alzheimer's?
- SignalThe "clinically meaningful" debate around CDR-SB is not settling
- SignalGantenerumab post-mortem: what the failure tells the field about Abeta-targeting